Absci Corp
NASDAQ:ABSI

Watchlist Manager
Absci Corp Logo
Absci Corp
NASDAQ:ABSI
Watchlist
Price: 2.75 USD -2.83%
Market Cap: 312.3m USD
Have any thoughts about
Absci Corp?
Write Note

Net Margin
Absci Corp

-2 321.6%
Current
-1 984%
Average
0%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-2 321.6%
=
Net Income
-97.7m
/
Revenue
4.2m

Net Margin Across Competitors

Country US
Market Cap 314m USD
Net Margin
-2 322%
Country US
Market Cap 1.3T USD
Net Margin
9%
Country US
Market Cap 196.2B USD
Net Margin
14%
Country US
Market Cap 170.9B USD
Net Margin
18%
Country KR
Market Cap 67.8T KRW
Net Margin
24%
Country CH
Market Cap 38.5B CHF
Net Margin
9%
Country US
Market Cap 38.6B USD
Net Margin
22%
Country US
Market Cap 36.5B USD
Net Margin
9%
Country US
Market Cap 26.7B USD
Net Margin
21%
Country US
Market Cap 23.2B USD
Net Margin
17%
Country US
Market Cap 23B USD
Net Margin
21%
No Stocks Found

Absci Corp
Glance View

Market Cap
314m USD
Industry
Life Sciences Tools & Services

Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. The company is headquartered in Vancouver Washington, Washington and currently employs 216 full-time employees. The company went IPO on 2021-07-22. The firm has developed an Integrated Drug Creation platform to identify novel drug targets, discover biotherapeutic candidates, and generate the cell lines to manufacture them in a single process. The company uses synthetic biology technologies and deep learning artificial intelligence (AI) to predict, identify, design, construct, screen, select and scale production of biologic drug candidates, and learn from the data it generates. The firm has drug candidates in approximately nine active programs, eight of the active programs are focused on developing production cell lines for drug candidates that the Company's partners are developing. The company has one discovery program, focused on lead optimization with Astellas. The Company’s active programs include Bispecific monoclonal antibodies (mAb), Bispecific T-cell engager, Cytokine, Fab, Multivalent Fc-fusion, Plasma protein and mAb.

ABSI Intrinsic Value
1.5 USD
Overvaluation 46%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-2 321.6%
=
Net Income
-97.7m
/
Revenue
4.2m
What is the Net Margin of Absci Corp?

Based on Absci Corp's most recent financial statements, the company has Net Margin of -2 321.6%.